Tissue and bone retention of gadolinium based contrast agents (GBCAs) has become a clinical concern because of the potential short and long term toxic effects of free gadolinium. This is a critical problem for most open-chain agents that more readily transmetallate in vivo, in comparison to macrocyclic compounds. Gadolinium diethylene tri-aminepentaacetic acid bis-glucosamide (Gd-DTPA-BIGA) is an experimental, open-chain contrast agent which has a significantly increased relaxivity coefficient in comparison to other GBCAs. This results in greater signal intensity and improved contrast enhancement. These superior imaging qualities initiated a search for a solution to the transmetallation of this agent. Plasma zinc is a well-known GBCA transmettalation agent. Since the base chelate of Gadodiamide (Gd-DPTA-Bis-Methylamide or Omniscan), DTPA-Bis-Methylamide (DTPA-BMA), readily transmettalates with and binds serum zinc, we hypothesized that a plasma "zinc sink," may significantly reduce transmetallation of linear agents. 5% DTPA-BMA was added to a formulation of Gd-DTPA-BIGA, which was tested against the original formulation of Gd-DTPA-BIGA with 0.2% of the base chelate DTPA-BIGA. These formulations, including gadodiamide, were labeled with GdCl followed by infusion into cohorts of Sprague Dawley rats which were sacrificed at 1, 30 and 60 days. Internal organs were harvested, along with blood, skin and femur, and analyzed for residual gadolinium. A subset of tissues were also interrogated with ICP-MS. Labeled Gadodiamide and saline where used as controls. Conclusion: The addition of 5% DTPA-BMA, as a zinc binding agent, reduced the transmetallation of the linear agent Gd-DTPA-BIGA, in comparison to its original formulation supplemented with 0.2% BIGA. This result indicates that supplementing linear GBCAs with ancillary chelates may hold promise for reducing, or eliminating the biological archiving of gadolinium in tissues. In addition, this paper provides valuable animal data on the long term retention of gadolinium from linear based contrast agents.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mri.2019.01.001DOI Listing

Publication Analysis

Top Keywords

contrast agents
12
gadolinium based
8
retention gadolinium
8
based contrast
8
long term
8
base chelate
8
transmetallation linear
8
formulation gd-dtpa-biga
8
original formulation
8
gadolinium
7

Similar Publications

Masticatory muscle changes on magnetic resonance imaging of dogs with compared to meningoencephalitis of unknown origin.

Front Vet Sci

January 2025

Anderson Moores Veterinary Specialists, Linnaeus Veterinary Limited, Winchester, United Kingdom.

Infectious meningoencephalitides represent an important differential diagnosis for meningoencephalitis of unknown origin (MUO) in dogs. Treatment of the latter requires immunosuppression, but laboratory test results for infectious agents may take several days to return. This study investigated whether the presence of masticatory muscle changes on magnetic resonance imaging (MRI) of the head can be used to distinguish dogs with neosporosis from those with MUO at the time of diagnosis.

View Article and Find Full Text PDF

Background: The bolus tracking technique has been used for decades, yet still faces the challenging task of determining the optimal scanning time for individuals. Our study aimed to assess the feasibility of a novel bolus tracking method with a personalized post-trigger delay (PTD) to optimize scanning time and achieve optimized enhancement and contrast homogeneity in aortic computed tomography angiography (CTA).

Methods: Participants undergoing aortic CTA with bolus tracking were prospectively assigned to two different groups: Group A with a fixed 6-second PTD and Group B with a personalized PTD.

View Article and Find Full Text PDF

Background: Gadolinium-based contrast agents (GBCAs) are usually employed for glioma diagnosis. However, GBCAs raise safety concerns, lead to patient discomfort and increase costs. Parametric maps offer a potential solution by enabling quantification of subtle tissue changes without GBCAs, but they are not commonly used in clinical practice due to the need for specifically targeted sequences.

View Article and Find Full Text PDF

An ASGP-R-targeting magnetic resonance imaging contrast agent for liver cancer diagnosis.

J Mater Chem B

January 2025

Department of Radiology, Huaxi MR Research Center (HMRRC), Institution of Radiology and Medical Imaging, Breast Center, Institute of Breast Health Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.

Development of novel Gd-based contrast agents for targeted magnetic resonance imaging (MRI) of liver cancer remains a great challenge. Herein we reported a novel Gd-based MRI contrast agent with improved relaxivity for specifically diagnosing liver cancer. This GSH-responsive macromolecular contrast agent (mCA), POLDGd, was prepared by RAFT polymerization, and its lactic acid moiety could precisely target the ASGP-R surface protein on liver cancer cells, whereas PODGd without the lactic acid moiety was prepared as a control.

View Article and Find Full Text PDF

Background And Purpose: The central vein sign (CVS) is a diagnostic imaging biomarker for multiple sclerosis (MS). FLAIR* is a combined MRI contrast that provides high conspicuity for CVS at 3 Tesla (3T), enabling its sensitive and accurate detection in clinical settings. This study evaluated whether CVS conspicuity of 3T FLAIR* is reliable across imaging sites and MRI vendors and whether gadolinium (Gd) contrast increases CVS conspicuity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!